32 results
To assess the safety and tolerability ofBNT141 at different dose levels.To identify the maximum tolerated dose (MTD) or maximally administered dose (MAD) /recommended Phase IIdose (RP2D) of BNT141 based on theoccurrence of dose-limiting toxicities(…
The MyKids study is a biological study towards the molecular profiling of pediatric NRSTS, the development of NRSTS tumoroid cultures, the establishment of liquid biopsy biomarkers and the molecular profiling of post-treatment tissue samples. The…
Primary:Phase 1: • To investigate the safety and tolerability, including identification of the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ZN-c3 in combination with gemcitabinePhase 2: • To evaluate the clinical activity of…
Primary Objective: To prospectively identify, in routine daily practice, the impact of radiotherapy to extremities, with regard to the incidence of (severe) ALT or AST elevations in STS patients (all grades, no systemic therapy). Secondary Objective…
The main aim is to test whether cetuximab-IRDye800CW is a reliable marker for residual tumor remnants in resection margins after surgical removal of head and neck cancer. To increase the specificity of cetuximab-800CW, a specific frozen section can…
The primary objective is to determine the clinical response of propranolol monotherapy in patients with angiosarcoma. The secondary endpoint is to assess the pathologic response of propranolol monotherapy in patients with angiosarcoma.
Dose Escalation: * To determine the MTD or the RP2D of tazemetostat when administered as an oral suspension BID in pediatric subjects with relapsed/refractory rhabdoid tumors, INI1-negative tumors or synovial sarcoma.* To evaluate the preliminary…
Part 11. Determine if accumulation of the fluorescent tracer bevacizumab-800CW can be detected for identification of soft tissue sarcoma during surgery.2. Identify two doses of bevacizumab-800CW that provide the best visualization of tumour tissue…
To study the feasibility of reducing the dose of preoperative radiotherapy in MLS from 50Gy to 36Gy while maintaining comparable clinicopathological responses.
if at least 50% of the obtained tumor samples will be viable and proliferating after 14 days (i.e. proliferation rate at day 14 is at least 50% of the proliferation rate at day 0), the ex vivo model will be considered as feasible
-To describe the differences in the parameters of physical exertion during physical activity with two different HMEs in both a lab and daily life setting-To asses patients* satisfaction with both types of HMEs
The main objective is to determine whether cabazitaxel demonstrates sufficient antitumor activity (as measured by progression free survival at 12 weeks) in pre-treated patients with metastatic or inoperable locally advanced DD liposarcoma to justify…